Q2 2026 saw a 4% revenue increase to $163.6M, driven by IP and equity gains, while net loss narrowed sharply to $8.4M. The oncology diagnostics divestiture and Nicoya equity deal boosted results, and cash reserves remain strong at $314.4M.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.